Nektar (NKTR) Says NKTR-102 Trial Did Not Achieve Statistical Significance

Nektar Therapeutics (NKTR) shares are currently halted in the extended session Tuesday following news that topline results from the company’s Phase 3 BEACON study evaluating single-agent NKTR-102 in patients with advanced breast cancer did not achieve statistical significance. The company said in a topline analysis of 852 patients from the trial, the drug, NKTR-102, provided […] View the full post at: Nektar (NKTR) Says NKTR-102 Trial Did Not Achieve Statistical Significance Related posts: Experimental Prostate-Cancer Drug Shows Promise Insider Selling: Twitter (TWTR) CEO Unloads $5M Worth of Stock